Technology | September 11, 2007

Carestream Health Highlighted New Dyes for In Vivo Imaging

Carestream Molecular Imaging, a division of Carestream Health, Inc., announced at the Joint Molecular Imaging Conference the introduction of KODAK X-SIGHT, new large stokes shift dyes for fluorescent in vivo imaging applications, which are reactive dyes designed to enable researchers and scientists to maximize the fluorescent signal while minimizing auto-fluorescence issues during in vivo imaging.

“Stokes shift” refers to the separation of absorption and emission maxima. Having a significantly larger Stokes shift—greater than 80 nanometers in the case of KODAK X-SIGHT Dyes—helps researchers eliminate much of the background that typically obstructs the fluorescent signal while allowing researchers to excite and emit the dyes at their maxima, thus resulting in far greater signal to noise. Most commercially available dyes typically have a Stokes shift between 20-30 nanometers.

In an organism, the KODAK X-SIGHT Dyes can illuminate a region of interest when excited by the appropriate wavelength of fluorescent light, thus allowing the researcher to visualize their target. While the KODAK X-SIGHT Imaging Agents have been optimized for KODAK Image Station and In-Vivo Systems, they are also compatible with other commercially available digital imaging systems.

“Our new KODAK X-SIGHT Large Stokes Shift Dyes, characterized by near infrared emission and a large Stokes shift, enable researchers to achieve a higher sensitivity of fluorescent detection deeper into tissue,” said Shahram Hejazi, PhD, President of Carestream Molecular Imaging. “With superior performance when compared to other commercially available products, these new dyes validate our outstanding dye chemistry expertise and leadership in fluorescent imaging.”
KODAK X-SIGHT Dyes will be available this fall for preclinical use.

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init